U.S. markets open in 3 hours 8 minutes
  • S&P Futures

    4,463.50
    -10.75 (-0.24%)
     
  • Dow Futures

    34,681.00
    -68.00 (-0.20%)
     
  • Nasdaq Futures

    15,494.50
    -23.25 (-0.15%)
     
  • Russell 2000 Futures

    2,219.70
    -8.20 (-0.37%)
     
  • Crude Oil

    71.92
    -0.69 (-0.95%)
     
  • Gold

    1,765.60
    +8.90 (+0.51%)
     
  • Silver

    23.08
    +0.29 (+1.28%)
     
  • EUR/USD

    1.1786
    +0.0014 (+0.12%)
     
  • 10-Yr Bond

    1.3310
    0.0000 (0.00%)
     
  • Vix

    19.23
    +1.05 (+5.78%)
     
  • GBP/USD

    1.3779
    -0.0017 (-0.13%)
     
  • USD/JPY

    109.9700
    +0.2520 (+0.23%)
     
  • BTC-USD

    47,634.88
    -318.43 (-0.66%)
     
  • CMC Crypto 200

    1,213.30
    -19.99 (-1.62%)
     
  • FTSE 100

    7,020.33
    -7.15 (-0.10%)
     
  • Nikkei 225

    30,500.05
    +176.71 (+0.58%)
     

U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer

Feb 2 (Reuters) - The U.S. Food and Drug Administration on Thursday expanded the use of Bristol-Myers Squibb Co's Opdivo to include treatment of urothelial carcinoma, the most common type of bladder cancer.

Opdivo, part of a new class of medicines designed to use the body's own immune system to fight cancer, is already approved to treat advanced melanoma, a form of lung cancer, kidney cancer, and Hodgkin lymphoma.

Investors were disappointed last month when Bristol-Myers said it would not seek accelerated FDA approval for a combination of Opdivo and another immunotherapy, Yervoy, as an initial treatment for lung cancer.

The FDA is slated to decide in May whether to approve rival Merck & Co Inc's combination of immunotherapy Keytruda and chemotherapy for first-line lung cancer.

(Reporting By Deena Beasley; editing by Diane Craft)